Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-62 in Obese Subjects with T2DM
NCT05409027Phase 1Completed
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of clofutriben in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Sparrow Pharmaceuticals. Primary endpoint: Maximum Plasma Concentration. Started Jul 2021; status: completed.
02
Drugs
clofutriben
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05409027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409027.